With Marijuana Rescheduling Still Pending, Federal Workplace Drug Testing Rules Aren’t Changing, Health Agency Says

Federal Workplace Drug Testing Rules: still stuck in neutral as marijuana rescheduling drags on. Picture a late-night diner at closing—fluorescents buzzing, coffee burnt, the specials board wiped clean. That’s federal cannabis policy right now: the kitchen’s open, but nothing new is coming out. Health officials just filed the paperwork that matters—the kind labs and medical review officers live by—and it says the testing menu hasn’t changed. No new cannabis carve-outs. No softened cutoffs. The authorized urine and oral-fluid panels remain the same, and the required nomenclature for what labs must report stays put. Because marijuana is still parked in Schedule I under the Controlled Substances Act, federal employees and safety-sensitive workers are dancing to the same old tune, whether their state dispensary is humming or not.

The notice is bureaucratic poetry—lean, cold, and consequential. It spells out analytes and cutoffs, and it dictates the precise names labs must use when they flag a specimen. By statute, the Department of Health and Human Services (HHS), in concert with the Substance Abuse and Mental Health Services Administration (SAMHSA), stands up every so often to say what’s changing or, like now, what isn’t. This round is the latter: no revisions to the current testing panels, no changes to the required report language. If you want to read the source document straight, it’s tucked into the Federal Register notice. Here’s the subtext that matters for policy watchers: HHS has already recommended moving cannabis to Schedule III, and a presidential directive told the Justice Department to get the rescheduling across the finish line. Yet the oven timer keeps ticking with no plated dish. Until the listing actually moves, the federal testing regime sits exactly where it’s been.

There’s one evolution worth noting, and it lives in the language. HHS cleaned up its cannabis terminology so labs and litigators aren’t talking past each other. Delta-9 THC is now called exactly that—delta-9 THC—rather than the vague “THC” that fails to distinguish it from delta-8, the hemp-derived cousin skulking around convenience-store counters. And the metabolite that labs measure is now delta-9 THCC, not “THCA,” which used to blur the line with the acidic, non-psychoactive form of THC found in raw flower. It’s housekeeping, sure, but the kind that keeps courts, compliance officers, and medical review officers aligned. Meanwhile, the Department of Transportation is harmonizing its own manuals but has been crystal clear about the bottom line: safety-sensitive workers still have to meet federal testing requirements, regardless of state legality or semantic finesse. And a former transportation boss put it plainly years ago—moving cannabis to Schedule III wouldn’t, by itself, lift testing for truckers, because DOT’s panel is its own gospel.

Follow the money, and you feel the grind even more. Rescheduling could expand research and—crucially for operators—change the calculus around that brutal tax code section, 280E. For now, the Internal Revenue Service is unmoved; cannabis businesses must keep paying as if nothing is changing, and any future relief won’t be retroactive. The attorney general was also supposed to help grease the skids for research on Schedule I substances, but a congressionally set deadline came and went with no final rules. Out in the states, the patchwork plays on like a roadhouse band: Alabama Medical Marijuana Sales Near Launch After Years Of Delay, while across the map, Texas Could See A Spike In Raids On Hemp Businesses Under New Rules, Industry Advocates Fear. One state pushes forward with regulated commerce; another tightens the screws on hemp storefronts. In the middle of it all, federal HR desks keep sliding the same forms across the counter: test, verify, report—no exceptions for a state card or a Friday-night gummy.

That’s the tension: a country where cannabis is sold in gleaming retail shops and, at the same time, a federal workplace where a trace metabolite can still end a career before lunch. Schedule III status could start to thaw parts of that ice—simpler research pathways, a saner tax burden—but don’t expect a light switch. The testing panels that bind federal employees sit on a different shelf, and agencies like DOT have their own reasons for keeping marijuana on the list. For employers outside the federal bubble, the smartest play is anticipation: update policies for clearer terminology (delta-9 THC versus delta-8), train managers on medical review officer processes, and keep a close eye on the final rule text when it lands. States will continue to spin the kaleidoscope—Virginia Lawmakers Pass Bill To Legalize Recreational Marijuana Sales, Sending It To Governor’s Desk while Oklahoma Lawmakers Reject Bill To Let Employers Fire More Workers For Using Medical Marijuana—but the federal frame is what decides who keeps their badge or their CDL.

So where does this leave you? In the liminal space—like nursing the last whiskey while the bartender stacks chairs—waiting for DOJ to stamp the rescheduling paperwork and for the testing rulemakers to say, at last, “Now we change.” Until then, federal workplace drug testing rules remain the same, and compliance is the name of the game. Workers should assume zero tolerance still applies, agencies should prepare for a terminology-accurate future, and businesses should plan for a tax regime that won’t blink until a final rule is inked. When the shift finally comes, it’ll come in stages: scheduling first, then tax relief and research access, and only later—if at all—revisions to the panels that decide careers. If you’ve read this far, you care about the difference between smoke and fire; when you’re ready to explore the hemp side of the spectrum, take a quiet stroll through our shop: https://thcaorder.com/shop/.